Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

NCT06526793 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06526793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06526793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
November 27, 2024
Completion date
October 21, 2032
Enrollment
270 (estimated)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma, follicular lymphoma (fl), large b-cell lymphoma (lbcl)